SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

$4CHAN is a meme token on the Ethereum Network.   4ChanToken represents a global crypto community that pays homage to the memetic powerhouses of the internet as Pepe, Doge, Shib and all major memes inventor combining them all into one super meme token that is $4CHAN. At its core, 4ChanToken embodies the untamed spirit of the notorious 4chan imageboard, where iconic memes are born, nurtured, and unleashed upon the world. With an unyielding spirit of irreverence and a touch of mischief, $4CHAN has emerged as the darling of meme enthusiasts, internet dwellers, and crypto aficionados alike.   The foundation of 4ChanToken lies in its community. We’ve harnessed the chaotic energy of this digital realm to create a currency that celebrates the power of memetic expression, empowering users to engage in a truly unique and decentralized economy. As a passionate supporter, you’ll join a vibrant ecosystem where dank memes and viral sensations are the lifeblood of commerce. 4ChanToken is more than just a digital currency – it’s the place where memes are born.  The ultimate playground for memelords and crypto degens. Based on the simplicity of holdrs/volume operating a store of value.  The identification of this value is best described as 'digital gold'. That $4chan can ultimately represent a superior store of value relative to all other forms of memecoins by embodying all memes in one token as the factual birthplace of all popular memes.

4Chan

Renewed speculative interest is centered on 4CHAN as an Ethereum-based, community-backed meme token, with supporters highlighting its very large token supply, claimed liquidity controls, growing holder base, and recent strength relative to major cryptocurrencies. Skeptics dispute the tokenomics and question whether the attention reflects a sustainable project or a pump-and-dump cycle.

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Attention is centered on Keetas rollout of fiat and payment infrastructure, particularly Keeta Personal with ACH capabilities, Visa Direct, LayerZero, and the UAE-based ASK Group tokenization partnership. Supporters view these developments as potential drivers of institutional volume, while skeptics point to delayed execution, limited on-chain usage, low liquidity, and lingering concerns from the security breach.

Direxion Shares ETF Trust - Direxion Daily S&P Biotech Bull 3X ETF

Direxion Daily S&P Biotech Bull 3X Shares

A sharp biotech-sector rally and XBI breakout, fueled by rotation from AI and semiconductor stocks alongside recurring biotech buyouts and positive clinical updates, has made LABU a high-volatility trading focus. Traders remain divided between expecting further upside and viewing the parabolic move as exhausted, with profit-taking, overbought conditions, and rising-yield concerns contributing to the pullback.

Dollar General Corp. engages in the operation of merchandise stores. Its offerings include food, snacks, health and beauty aids, cleaning supplies, basic apparel, housewares, and seasonal items. It sells brands including Clorox, Energizer, Procter & Gamble, Hanes, Coca-Cola, Mars, Unilever, Nestle, Kimberly-Clark, Kellogg's, General Mills, and PepsiCo. The company was founded by J. L. Turner and Hurley Calister Turner Sr. in 1939 and is headquartered in Goodlettsville, TN.

Dollar General Corp.

A stronger-than-expected second-quarter report and raised full-year outlook, supported by traffic-led comparable sales, margin improvement and planned share repurchases, have put Dollar General in focus. Traders are debating whether the gains reflect a durable turnaround and value-shopping tailwind or are vulnerable to profit-taking and concerns about one-time tariff benefits and broader consumer pressure.

Select Sector SPDR Trust (The) - State Street Technology Select Sector SPDR ETF

Technology Select Sector SPDR Fund

Higher Treasury yields and renewed skepticism over AI spending, valuations, and semiconductor momentum are pressuring XLK as the recent technology rally reverses. Traders are divided between viewing the weakness as a healthy pullback and expecting further downside amid rotation toward energy, healthcare, and financials.

Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company, which engages in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its pipeline includes Aleniglipron GSBR-1290, ACCG-2671, GIPR, GCGR, ANPA-0073, and LTSE-2578. The company was founded by Raymond C. Stevens in 2016 and is headquartered in South San Francisco, CA.

Structure Therapeutics Inc - ADR

Anticipation of Structures ACCESS OLE and oral amylin data releases is driving attention, alongside speculation that positive readouts could prompt a Big Pharma partnership or buyout before Phase 3. Traders remain divided, with bulls emphasizing the oral GLP-1s efficacy and potential deal value while skeptics question tolerability, liver-safety risk, and whether any transaction is imminent.

Oxford Lane Capital Corp. is a closed-end management investment company, which engages in investing in debt and equity tranches of collateralized loan obligation vehicles. The company was founded on June 9, 2010 and is headquartered in Greenwich, CT.

Oxford Lane Capital Corp

Oxford Lanes July NAV update, showing NAV above the common share price, alongside continued monthly distributions through year-end, has driven renewed buying and discussion of a recovery toward NAV. Bullish traders view the discount and income as attractive, while critics focus on the earlier distribution cut, weak CLO credit markets, NAV erosion, and risk of further deterioration.

NEOS ETF Trust - NEOS Nasdaq 100 High Income ETF

NEOS Nasdaq 100 High Income ETF

Monthly income distributions and the ETFs high-yield Nasdaq covered-call strategy are driving attention, with investors discussing ex-dividend timing, reinvesting payouts, and using pullbacks to accumulate. Debate centers on whether the income and tax advantages offset capped upside, potential NAV erosion, and weaker long-term growth versus QQQ or competing funds such as JEPQ.

Direxion Shares ETF Trust - Direxion Daily MU Bull 2X ETF

Direxion Daily MU Bull 2X Shares

Microns strong earnings and bullish AI-memory demand outlook are driving interest in MUU, with traders using the 2x leveraged ETF to amplify the underlying move while debating further upside versus profit-taking and volatility decay. The community is also focused on MUUs 20-for-1 forward split, which caused confusion over its lower quoted price and adjusted share counts.

Visa, Inc. engages in the provision of digital payment services. It also facilitates global commerce through the transfer of value and information among a global network of consumers, merchants, financial institutions, businesses, strategic partners, and government entities. It offers debit cards, credit cards, prepaid products, commercial payment solutions, and global automated teller machines. The company was founded by Dee Hock in 1958 and is headquartered in San Francisco, CA.

Visa Inc - Ordinary Shares - Class A

Visa Inc

Visa is drawing attention after reaching fresh 52-week and all-time highs, with traders citing resilient payment growth, a fiscal Q3 earnings beat, buybacks, and institutional interest including Bill Ackmans disclosed stake. Sentiment is broadly bullish, though some traders warn the stock is overbought and vulnerable to profit-taking, while others debate stablecoins as a longer-term competitive risk.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Notable Wednesday Option Activity: ZVRA, KOD, PEN

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Zevra Therapeutics, Inc (Symbol: ZVRA), where a total volume of 8,827 contracts has been traded thus far today, a contract volume which is representative of appr...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA PR Newswire NEW YORK, Aug. 6, 2026 NEW YORK, Aug. 6, 2026 /PRNewswire...

Zevra Therapeutics (ZVRA) Q2 Earnings and Revenues Surpass Estimates

Zevra Therapeutics (ZVRA) delivered earnings and revenue surprises of +212.50% and +22.76%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Zevra Therapeutics (ZVRA) Securities Investigation Notice - Levi & Korsinsky

Zevra Therapeutics (ZVRA) Securities Investigation Notice - Levi & Korsinsky Zevra Therapeutics (ZVRA) Securities Investigation Notice - Levi & Korsinsky PR Newswire NEW YORK, Aug. 3, 2026 Zevra investors who relied on public statements about arimoclomol's approval status faced losses after the...

Ono Pharmaceutical Co. (OPHLF) Q1 Earnings and Revenues Top Estimates

Ono Pharmaceutical Co. (OPHLF) delivered earnings and revenue surprises of +60.00% and +5.04%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA PR Newswire NEW YORK, July 30, 2026 NEW YORK, July 30, 2026 /PRNewswire...

ZVRA Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Zevra Therapeutics (ZVRA)

On July 24, 2026, Zevra Therapeutics (NASDAQ: ZVRA) shares fell approximately 24% after the European Medicines Agency's Committee for Medicinal Products for Human Use issued a negative opinion on the Marketing Authorization Application for arimoclomol, branded Meplyffa, for Niemann-Pick disease...

ZVRA SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Zevra Therapeutics

ZVRA SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Zevra Therapeutics ZVRA SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Zevra Therapeutics PR Newswire NEW YORK, July 28, 2026 Zevra shareholders...

ZVRA Investors Have Opportunity to Join Zevra Therapeutics, Inc. Fraud Investigation with SBS Law

Schall, Brown & Schwartz LLP (SBS), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zevra Therapeutics, Inc. (Zevra or the Company) (NASDAQ: ZVRA) for violations of the securities laws.INVESTIGATION DETAILS: The investigation...

Zevra Therapeutics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Zevra Therapeutics (ZVRA)

Zevra Therapeutics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Zevra Therapeutics (ZVRA) Zevra Therapeutics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Zevra Therapeutics (ZVRA) PR Newswire NEW YORK, July 27...

• Reported GAAP EPS of $0.14 down -88.71% YoY
• Reported revenue of $39.66M up 53.25% YoY

Zevra Therapeutics experienced a significant year-over-year decline in net income, while safety risks including hypersensitivity reactions and uncertainties regarding the clinical significance of therapeutic mechanisms remain key business challenges.

Zevra Therapeutics delivered strong revenue growth and expanded its intellectual property protection for MIPLYFFA, while continuing to advance the clinical development of its pipeline candidate celiprolol for Vascular Ehlers-Danlos Syndrome.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

ZVRA Stock Sinks 23% On EU Setback — Analyst Says Risk Is ‘A Headwind, But Not Insurmountable’

Equity

Neutral Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

The S&P 500 ($SPY) is headed towards a positive week. What do you think the index's return will look like next week? Vote and explain your reasoning in the comments.

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '26	$0.16	--	--	N/A
Q2 '26	$0.11	$0.14	27.27%	BEAT
Q1 '26	$0.08	$0.60	639.73%	BEAT
Q4 '25	$0.05	$0.19	276.98%	BEAT
Q3 '25	-$0.03	-$0.01	70.37%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q2 '26

Historical Earnings